We are live on ! Find out more
IMDZ

Immune Design Corp.
IMDZ

Delisted

IMDZ was delisted on the 1st of April, 2019.

0 hedge funds and large institutions have $0 invested in Immune Design Corp. in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 66 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 680 (-68)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

100% less capital invested

Capital invested by funds: $165M → $0 (-$165M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 66

Holders
Holders Change
-68
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
Increased
Reduced
Closed
66
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

IMDZ Hedge Fund Activity: Q2 2019 in Review

0 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Immune Design Corp. (IMDZ) for Q2 2019, worth a combined $0 — down 100% from $165M a quarter earlier.

Sellers outnumbered buyers: 66 funds closed out of IMDZ and 0 opened new positions — a net loss of 66 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Peter Svennilson, exiting entirely with an estimated $38.9M sold.

  • 0 institutional investors held Immune Design Corp. (IMDZ) as of Q2 2019, down from 68 in Q1 2019.
  • Funds reported $0 of Immune Design Corp. stock for Q2 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Immune Design Corp. positions in Q2 2019 and 66 closed out, a net change of -66 holders.
  • The largest Immune Design Corp. seller in Q2 2019 was Peter Svennilson, an estimated $38.9M sold.

Based on aggregated 13F filings for Q2 2019.